You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 9,440,034


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,440,034
Title:Drug condensation aerosols and kits
Abstract: The present invention provides novel condensation aerosols for the treatment of disease and/or intermittent or acute conditions. These condensation aerosols have little or no pyrolysis degradation products and are characterized by having an MMAD of between 1-3 microns. These aerosols are made by rapidly heating a substrate coated with a thin film of drug having a thickness of between 0.05 and 20 .mu.m, while passing a gas over the film, to form particles of a desirable particle size for inhalation. Kits comprising a drug and a device for producing a condensation aerosol are also provided. The device contained in the kit typically, has an element for heating the drug which is coated as a film on the substrate and contains a therapeutically effective dose of a drug when the drug is administered in aerosol form, and an element allowing the vapor to cool to form an aerosol. Also disclosed, are methods for using these aerosols and kits.
Inventor(s): Hale; Ron L. (Sandia Park, NM), Hodges; Craig C. (Walnut Creek, CA), Lloyd; Peter M. (Walnut Creek, CA), Lu; Amy T. (Los Altos, CA), Myers; Daniel J. (Mountain View, CA), Rabinowitz; Joshua D. (Princeton, NJ), Wensley; Martin J. (Los Gatos, CA), McKinney; Jeffrey A. (Lafayette, CA), Zaffaroni; Alejandro C. (Atherton, CA)
Assignee: ALEXZA PHARMACEUTICALS, INC. (Mountain View, CA)
Application Number:14/078,679
Patent Claim Types:
see list of patent claims
Composition; Delivery; Device; Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 9,440,034: A Detailed Analysis

Introduction

United States Patent 9,440,034, though not directly provided in the sources, can be analyzed through the lens of general patent law and recent updates in patent eligibility criteria. This article will delve into the key aspects of patent scope, claims, and the broader patent landscape, using relevant examples and guidelines to illustrate the points.

Patent Scope and Claims

Definition and Importance

Patent scope and claims are crucial elements of a patent application. The scope defines the boundaries of what is protected, while the claims specify the exact invention for which protection is sought[3].

Claim Construction

Claim construction is a critical step in determining the scope of a patent. It involves interpreting the language of the claims to understand what is covered by the patent. This process is often subject to legal scrutiny, as seen in cases like Contour IP Holding LLC v. GoPro, Inc., where claim terms are disputed and construed by the court[2].

Patent Eligibility Criteria

Section 101 of the Patent Act

Section 101 of the Patent Act states that whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor. However, certain exceptions exist, such as laws of nature, natural phenomena, and abstract ideas, which are not patentable[2].

The Alice Test

The Supreme Court's Alice test is a two-step framework for determining whether patent claims are directed to patent-ineligible subject matter. Step one involves determining if the claims are directed to an abstract idea. If they are, the inquiry proceeds to step two, where it is assessed whether the claims recite something "significantly more" than the abstract idea itself[2].

Recent USPTO Guidance on AI Patents

2024 USPTO Guidance Update

The 2024 USPTO guidance update on AI patents refines the process for determining the patent eligibility of AI-related inventions. It emphasizes evaluating whether a claim integrates a judicial exception into a practical application, ensuring that the claimed invention offers a concrete technological improvement. This guidance is crucial for drafting claims that avoid section 101 rejections[4].

AI-Assisted Inventions

The update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[4].

Practical Applications and Real-World Benefits

Integrating Abstract Ideas into Practical Applications

To be patent-eligible, claims must integrate abstract ideas into practical applications. For example, a claim that merely uses a mathematical model to manipulate data without applying it in a specific manner does not meet the criteria. However, a claim that specifies the use of separated audio components in a real-time speech recognition system to enhance accuracy in hands-free environments does provide a practical application and is thus patent-eligible[4].

Statistical and Data-Driven Insights

Patent Claims Research Dataset

The Patent Claims Research Dataset, provided by the USPTO, contains detailed information on claims from U.S. patents granted between 1976 and 2014 and U.S. patent applications published between 2001 and 2014. This dataset helps in understanding trends and measurements of patent scope, which can be invaluable in drafting and evaluating patent claims[3].

Case Law and Precedents

Contour IP Holding LLC v. GoPro, Inc.

In Contour IP Holding LLC v. GoPro, Inc., the court reviewed the grant of a summary judgment and applied the Alice test to determine patent eligibility. This case highlights the importance of claim construction and the application of legal precedents in patent disputes[2].

Human Contribution and Technological Improvement

Significant Human Contribution

The 2024 USPTO guidance emphasizes that AI-assisted inventions must show significant human contribution to be eligible for patents. This ensures that the role of AI as a tool does not exclude inventions from eligibility, provided there is meaningful human input[4].

Real-World Applications

Demonstrating Practical Utility

Highlighting the real-world applications of the claimed method or system is crucial for bolstering the argument for patent eligibility. Demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field is essential for meeting the criteria for patent eligibility[4].

Key Takeaways

  • Patent Scope and Claims: The scope defines the boundaries of what is protected, while the claims specify the exact invention.
  • Patent Eligibility: Section 101 of the Patent Act and the Alice test are key in determining patent eligibility, especially for abstract ideas.
  • AI Patents: The 2024 USPTO guidance update clarifies the process for AI-related inventions, emphasizing practical applications and significant human contribution.
  • Practical Applications: Claims must integrate abstract ideas into practical applications to be patent-eligible.
  • Statistical Insights: The Patent Claims Research Dataset provides valuable information on patent scope and trends.

FAQs

What is the significance of claim construction in patent law?

Claim construction is critical as it determines the scope of what is protected by the patent, often subject to legal scrutiny.

How does the Alice test impact patent eligibility?

The Alice test is a two-step framework that determines whether claims are directed to abstract ideas and if they recite something "significantly more" than the abstract idea itself.

What does the 2024 USPTO guidance update on AI patents emphasize?

The update emphasizes integrating judicial exceptions into practical applications and ensuring significant human contribution in AI-assisted inventions.

Why is it important to demonstrate real-world applications in patent claims?

Demonstrating real-world applications shows how the abstract idea is applied in a way that provides concrete benefits, which is crucial for meeting patent eligibility criteria.

How does the Patent Claims Research Dataset help in patent analysis?

The dataset provides detailed information on claims and trends, helping in understanding patent scope and drafting effective patent claims.

Sources

  1. United States Patent and Trademark Office, Patent Claims Research Dataset, https://www.uspto.gov/ip-policy/economic-research/research-datasets/patent-claims-research-dataset
  2. United States Court of Appeals for the Federal Circuit, Contour IP Holding LLC v. GoPro, Inc., https://cafc.uscourts.gov/opinions-orders/22-1654.OPINION.9-9-2024_2381170.pdf
  3. Mintz, Understanding the 2024 USPTO Guidance Update on AI Patent, https://www.mintz.com/insights-center/viewpoints/2231/2024-07-24-understanding-2024-uspto-guidance-update-ai-patent
  4. Unified Patents, US-5229120-A - Treatment for Cocaine Abuse, https://portal.unifiedpatents.com/patents/patent/US-5229120-A

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,440,034

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,440,034

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1389098 ⤷  Subscribe C300609 Netherlands ⤷  Subscribe
European Patent Office 1389098 ⤷  Subscribe CA 2013 00046 Denmark ⤷  Subscribe
European Patent Office 1389098 ⤷  Subscribe CR 2013 00046 Denmark ⤷  Subscribe
European Patent Office 1389098 ⤷  Subscribe 1390040-2 Sweden ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.